On June 5, our Indian subsidiary launched its second oncology treatment. After 38 years of strong presence in cardiovascular and metabolic diseases in India and launching its first drug in oncology for pancreatic cancer, we have reached a new stage in our oncology ambitions.
A reason for hope for patients with cancer
With an estimated 14.6 million new cases of cancer in 20221, India is facing a major challenge. In fact, one person out of nine is likely to develop cancer during their life1.
“Our objective is to advance oncology care by providing innovative and precision medicines to patients with high medical needs. This launch is a major step in our healthcare professional support mission via targeted therapeutic options, in order to improve survival and quality of life of patients throughout India.”
Aurélien Breton, Managing Director of Servier India
With the introduction of these advanced therapies, Servier India reaffirms its commitment to advancing innovative oncology treatments and improving patients’ quality of life.
With a clear ambition: becoming a focused and innovative player in rare cancer treatments
According to the World Health Organization, cancer is the second cause of mortality in the world2, and is constantly progressing. In view of the increasing needs for therapeutic solutions, we have made oncology one of our priority innovation lines.
Providing this treatment in India is in line with our Servier 2030 ambition of becoming a focused and innovative player in rare cancer treatments. Our commitment in the fight against cancer is currently reflected in the eight treatments made available for patients in the world, and nearly 70 % of our R&D budget dedicated to oncology.
Servier in India in figures
[1] https://pubmed.ncbi.nlm.nih.gov/36510887/#:~:text=The%20age%2Dspecific%20incidence%20rate,rate%3A100.4%20per%20100%2C000)
[2] https://www.who.int/fr/health-topics/cancer#tab=tab_1
